Sarah Wood Pallas1, Marissa Courey2, Chhaily Hy3, Wm Perry Killam3, Dora Warren3, Brittany Moore4. 1. Division of Global HIV/AIDS, Center for Global Health, US Centers for Disease Control and Prevention (CDC), 1600 Clifton Road NE, MS A-04, Atlanta, GA, 30329-4027, USA. spallas@cdc.gov. 2. Division of Global HIV/AIDS, Center for Global Health, US Centers for Disease Control and Prevention (CDC), 1600 Clifton Road NE, MS A-04, Atlanta, GA, 30329-4027, USA. 3. Division of Global HIV/AIDS, Center for Global Health, US Centers for Disease Control and Prevention (CDC), National Institute of Public Health, #80, 289 Samdach Penn Nouth St. (289), Phnom Penh, Cambodia. 4. Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention (CDC), 1600 Clifton Road NE, Atlanta, GA, 30329-4027, USA.
Abstract
BACKGROUND: The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert's cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB burden, and low multidrug-resistant (MDR) TB burden (1.4% of new TB cases, 11% of retreatment cases) introduced Xpert into its TB diagnostic algorithms for people living with HIV (PLHIV) and people with presumptive MDR TB in 2012. The study objective was to estimate these algorithms' costs pre- and post-Xpert introduction in four provinces of Cambodia. METHODS: Using a retrospective, ingredients-based microcosting approach, primary cost data on personnel, equipment, maintenance, supplies, and specimen transport were collected at four sites through observation, records review, and key informant consultations. RESULTS: Across the sample facilities, the cost per Xpert test was US$33.88-US$37.11, clinical exam cost US$1.22-US$1.84, chest X-ray cost US$2.02-US$2.14, fluorescent microscopy (FM) smear cost US$1.56-US$1.93, Ziehl-Neelsen (ZN) smear cost US$1.26, liquid culture test cost US$11.63-US$22.83, follow-on work-up for positive culture results and Mycobacterium tuberculosis complex (MTB) identification cost US$11.50-US$14.72, and drug susceptibility testing (DST) cost US$44.26. Specimen transport added US$1.39-US$5.21 per sample. Assuming clinician adherence to the algorithms and perfect test accuracy, the normative cost per patient correctly diagnosed under the post-Xpert algorithms would be US$25-US$29 more per PLHIV and US$34-US$37 more per person with presumptive MDR TB (US$41 more per PLHIV when accounting for variable test sensitivity and specificity). CONCLUSIONS: Xpert test unit costs could be reduced through lower cartridge prices, longer usable life of GeneXpert® (Cepheid, USA) instruments, and increased test volumes; however, epidemiological and test eligibility conditions in Cambodia limit the number of specimens received at laboratories, leading to sub-optimal utilization of current instruments. Improvements to patient referral and specimen transport could increase test volumes and reduce Xpert test unit costs in this setting.
BACKGROUND: The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert's cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB burden, and low multidrug-resistant (MDR) TB burden (1.4% of new TB cases, 11% of retreatment cases) introduced Xpert into its TB diagnostic algorithms for people living with HIV (PLHIV) and people with presumptive MDR TB in 2012. The study objective was to estimate these algorithms' costs pre- and post-Xpert introduction in four provinces of Cambodia. METHODS: Using a retrospective, ingredients-based microcosting approach, primary cost data on personnel, equipment, maintenance, supplies, and specimen transport were collected at four sites through observation, records review, and key informant consultations. RESULTS: Across the sample facilities, the cost per Xpert test was US$33.88-US$37.11, clinical exam cost US$1.22-US$1.84, chest X-ray cost US$2.02-US$2.14, fluorescent microscopy (FM) smear cost US$1.56-US$1.93, Ziehl-Neelsen (ZN) smear cost US$1.26, liquid culture test cost US$11.63-US$22.83, follow-on work-up for positive culture results and Mycobacterium tuberculosis complex (MTB) identification cost US$11.50-US$14.72, and drug susceptibility testing (DST) cost US$44.26. Specimen transport added US$1.39-US$5.21 per sample. Assuming clinician adherence to the algorithms and perfect test accuracy, the normative cost per patient correctly diagnosed under the post-Xpert algorithms would be US$25-US$29 more per PLHIV and US$34-US$37 more per person with presumptive MDR TB (US$41 more per PLHIV when accounting for variable test sensitivity and specificity). CONCLUSIONS: Xpert test unit costs could be reduced through lower cartridge prices, longer usable life of GeneXpert® (Cepheid, USA) instruments, and increased test volumes; however, epidemiological and test eligibility conditions in Cambodia limit the number of specimens received at laboratories, leading to sub-optimal utilization of current instruments. Improvements to patient referral and specimen transport could increase test volumes and reduce Xpert test unit costs in this setting.
Authors: Karen R Steingart; Megan Henry; Vivienne Ng; Philip C Hopewell; Andrew Ramsay; Jane Cunningham; Richard Urbanczik; Mark Perkins; Mohamed Abdel Aziz; Madhukar Pai Journal: Lancet Infect Dis Date: 2006-09 Impact factor: 25.071
Authors: Taiwo O Abimbola; Barbara J Marston; Anand A Date; John M Blandford; Nalinee Sangrujee; Stefan Z Wiktor Journal: J Acquir Immune Defic Syndr Date: 2012-05-01 Impact factor: 3.731
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: D C Perlman; W M el-Sadr; E T Nelson; J P Matts; E E Telzak; N Salomon; K Chirgwin; R Hafner Journal: Clin Infect Dis Date: 1997-08 Impact factor: 9.079
Authors: A Tucker; D Oyuku; T Nalugwa; M Nantale; O Ferguson; K Farr; T F Reza; P B Shete; A Cattamanchi; D W Dowdy; H Sohn; A Katamba Journal: Int J Tuberc Lung Dis Date: 2021-01-01 Impact factor: 2.373
Authors: Alvin Kuo Jing Teo; Kiesha Prem; Yi Wang; Tripti Pande; Marina Smelyanskaya; Lisanne Gerstel; Monyrath Chry; Sovannary Tuot; Siyan Yi Journal: Int J Environ Res Public Health Date: 2021-12-02 Impact factor: 3.390
Authors: Eva Glaeser; Bart Jacobs; Bernd Appelt; Elias Engelking; Ir Por; Kunthea Yem; Steffen Flessa Journal: Int J Environ Res Public Health Date: 2020-11-02 Impact factor: 3.390